Lixte Biotechnology Holdings Inc. Warrants (LIXTW)
$0.02
$0.00
(-0.45%)
As on 28-Nov-2025 09:30EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
10 Years Aggregate
CFO
$-25.27 Mln
EBITDA
$-34.42 Mln
Net Profit
$-35.48 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Lixte Biotechnology Holdings Inc. Warrants (LIXTW)
| -24.1 | -84.0 | -89.3 | -21.1 | -36.3 | -54.4 | -- |
|
BSE Sensex*
| -9.4 | -2.5 | 3.2 | -4.8 | 5.5 | 5.7 | 10.4 |
|
Company
|
2024
|
2023
|
|---|---|---|
|
Lixte Biotechnology Holdings Inc. Warrants (LIXTW)
| -23.7 | -35.6 |
|
BSE Sensex
| 8.1 | 18.7 |
|
BSE Sensex
| 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Lixte Biotechnology Holdings Inc. Warrants (LIXTW)
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b... clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California. Read more
-
President, CEO & Chairman of the Board of Directors
Mr. Bastiaan van der Baan M.Sc.
-
President, CEO & Chairman of the Board of Directors
Mr. Bastiaan van der Baan M.Sc.
-
Headquarters
Pasadena, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Lixte Biotechnology Holdings Inc. Warrants (LIXTW)
What is the current share price of Lixte Biotechnology Holdings Inc Warrants (LIXTW) Today?
The share price of Lixte Biotechnology Holdings Inc Warrants (LIXTW) is $0.02 (NASDAQ) as of 28-Nov-2025 09:30 EDT. Lixte Biotechnology Holdings Inc Warrants (LIXTW) has given a return of -36.27% in the last 3 years.
What is the current PB & PE ratio of Lixte Biotechnology Holdings Inc Warrants (LIXTW)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2024 |
-0.02 |
0.08 |
2023 |
-0.02 |
0.02 |
2022 |
-0.02 |
0.02 |
2021 |
-0.09 |
0.13 |
2020 |
-0.32 |
0.21 |
What is the 52 Week High and Low of Lixte Biotechnology Holdings Inc Warrants (LIXTW)?
The 52-week high and low of Lixte Biotechnology Holdings Inc Warrants (LIXTW) are Rs 0.38 and Rs 0.01 as of 04-Sep-2026.
What is the market cap of Lixte Biotechnology Holdings Inc Warrants (LIXTW)?
Lixte Biotechnology Holdings Inc Warrants (LIXTW) has a market capitalisation of $ 39 Mln as on 28-Nov-2025. As per SEBI classification, it is a company.
Should I invest in Lixte Biotechnology Holdings Inc Warrants (LIXTW)?
Before investing in Lixte Biotechnology Holdings Inc Warrants (LIXTW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.